![]() | |
Names | |
---|---|
Preferred IUPAC name
4-{6-[4-(Piperazin-1-yl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl}quinoline | |
Identifiers | |
3D model (
JSmol)
|
|
PubChem
CID
|
|
UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C25H22N6 | |
Molar mass | 406.493 g·mol−1 |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
LDN193189 is a chemical compound used in the study of bone morphogenetic protein signalling through the ALK2, ALK3 and ALK6 receptors. [1] It has been researched for the treatment of fibrodysplasia ossificans progressiva. [2]
![]() | |
Names | |
---|---|
Preferred IUPAC name
4-{6-[4-(Piperazin-1-yl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl}quinoline | |
Identifiers | |
3D model (
JSmol)
|
|
PubChem
CID
|
|
UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C25H22N6 | |
Molar mass | 406.493 g·mol−1 |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
LDN193189 is a chemical compound used in the study of bone morphogenetic protein signalling through the ALK2, ALK3 and ALK6 receptors. [1] It has been researched for the treatment of fibrodysplasia ossificans progressiva. [2]